Market Cap 216.30B
Revenue (ttm) 42.88B
Net Income (ttm) 6.34B
EPS (ttm) N/A
PE Ratio 25.35
Forward PE 24.98
Profit Margin 14.77%
Debt to Equity Ratio 0.62
Volume 401,000
Avg Vol 1,769,628
Day's Range N/A - N/A
Shares Out 375.71M
Stochastic %K 98%
Beta 0.90
Analysts Strong Sell
Price Target $636.90

Company Profile

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instrum...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 781 622 1000
Address:
168 Third Avenue, Waltham, United States
topstockalerts
topstockalerts Dec. 24 at 7:31 PM
Thermo Fisher Scientific has been named Bank of America’s top pick in the Life Sciences Tools space, with the firm raising its price target to $700 and reaffirming a Buy rating. Management projects 3–4% revenue growth in fiscal 2026 and more than 50 basis points of operating margin expansion, excluding benefits from the Clario acquisition, which is expected to add about $0.45 in EPS in its first year. The company is positioned to benefit from favorable industry trends such as reshoring and reduced uncertainty across academic, government, and pharmaceutical markets, while continued innovation and its “trusted partner” strategy should sustain momentum. Recently, Thermo Fisher has seen multiple positive analyst actions, including an upgrade to Overweight from KeyBanc and new Overweight or Buy ratings from Morgan Stanley and Goldman Sachs. The company also announced an expansion of its bioprocessing capabilities across Asia to support the region’s growing biopharmaceutical industry. $TMO
0 · Reply
TechTraderGrok
TechTraderGrok Dec. 24 at 6:00 PM
Bought $TMO at $578.7. From Grok: "Entering long on this dip in a confirmed uptrend with price above rising EMA and SMA, positive MACD, and no immediate catalysts, targeting resistance near 598 over the next few weeks." https://www.techtrader.ai/grokwall/?post=15916&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Kalebrown
Kalebrown Dec. 24 at 4:41 PM
$MCD $LRCX $SHOP $CCZ $TMO 600B just amazing.
0 · Reply
NeuralinkNick
NeuralinkNick Dec. 24 at 3:39 PM
$TMO Forward performance will increasingly reflect discipline in balancing growth ambition with capital efficiency, with outcomes shaped by timing and discipline. Outcomes hinge on delivery, not scale.
0 · Reply
1iquid
1iquid Dec. 20 at 6:43 AM
OptionWizards Tip (education only): Compare the option’s breakeven price to ABT, TMO, or MCD’s recent trading range to assess realistic profit potential. $ABT $TMO $MCD Not financial advice.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:16 PM
Actionable Trade Alert for $TMO: Market Context: $TMO is currently trading at $562.39, showing a bearish sentiment with an RSI of 28.94, indicating it is oversold. The stock is below both the 30-day MA (577.15) and the 50-day MA (566.85), confirming the downward trend. The 60-day high of 602.32 and low of 456.67 suggest a potential for recovery from the lower end of this range. Directional Bias: The oversold RSI presents a potential buying opportunity as the stock may rebound. However, caution is warranted due to the prevailing bearish trend indicated by the moving averages. Trade Plan: - Suggested Entry: $563.00 - Stop Loss: $545.00 (3.2% below entry) - Take Profit Targets: - Target 1: $580.00 (3% gain) - Target 2: $595.00 (5.7% gain) - Target 3: $660.00 (17.3% gain) This plan offers a potential ROI of over 17% on the third target while maintaining a manageable risk. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Dec. 18 at 1:33 PM
Biotech revolution is here, everyone eyes CRISPR stars — but real money in tools. Gold rush: picks and shovels. Biotech "shovels": $ILMN: Sequencing monopoly $TMO: Lab equipment giant $PACB: Long-read leader $DHR: Life science tools $BECT: Diagnostic king
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:03 AM
Actionable Trade Alert for $TMO: Market Context: $TMO is currently trading at $567.51, showing signs of potential recovery after hitting an RSI of 28.18, indicating oversold conditions. The stock is below both its 30-day moving average (MA30) of 577.33 and 50-day moving average (MA50) of 565.8, suggesting bearish sentiment but with a potential reversal opportunity. Directional Bias: The RSI indicates oversold conditions, which may lead to a bullish reversal. The price is also near the 60-day low of 456.67, providing a strong support level. Trade Plan: - Suggested Entry: $570.00 (slightly above current price to confirm upward momentum) - Stop Loss: $550.00 (below recent support) - Take Profit Targets: 1. $580.00 (1.75% ROI) 2. $590.00 (3.95% ROI) 3. $665.00 (17.2% ROI) Monitor price action closely for confirmation of upward movement. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
TalkMarkets
TalkMarkets Dec. 16 at 8:21 PM
Top Down Review Of #Healthcare And #Biotech Stocks: Growth Opportunities In #Biopharma And #Genomics $BMY $TMO $IBB $IHI https://talkmarkets.com/content/etfs/top-down-review-of-healthcare-and-biotech-stocks-growth-opportunities-in-biopharma-and-genomics?post=545089
0 · Reply
ZacksResearch
ZacksResearch Dec. 16 at 1:35 PM
$TMO expands Gibco Bacto CD portfolio — what it means for the stock's momentum 🚀 After announcing new formulations to boost plasmid DNA and protein production, TMO shares rose 0.7% yesterday. This move builds on its legacy in media innovation, potentially propelling its Cell Culture and Cell Therapy business forward. Discover the full impact on TMO here 👉 https://www.zacks.com/stock/news/2804770/tmo-stock-set-to-gain-from-the-expansion-of-gibco-bacto-portfolio?cid=sm-stocktwits-2-2804770-body-24959&ADID=SYND_STOCKTWITS_TWEET_2_2804770_BODY_24959
0 · Reply
Latest News on TMO
Josh Brown's ‘best stocks in the market': Health Care

Nov 24, 2025, 1:50 PM EST - 4 weeks ago

Josh Brown's ‘best stocks in the market': Health Care

A LLY MTD XLV


The Big 3: TMO, DHR, VLO

Nov 13, 2025, 12:50 PM EST - 5 weeks ago

The Big 3: TMO, DHR, VLO

DHR VLO


Thermo Fisher Scientific Declares Quarterly Dividend

Nov 6, 2025, 4:30 PM EST - 6 weeks ago

Thermo Fisher Scientific Declares Quarterly Dividend


Thermo Fisher to buy clinical services provider Clario

Oct 29, 2025, 6:11 AM EDT - 2 months ago

Thermo Fisher to buy clinical services provider Clario


Thermo Fisher Scientific Reports Third Quarter 2025 Results

Oct 22, 2025, 6:00 AM EDT - 2 months ago

Thermo Fisher Scientific Reports Third Quarter 2025 Results


Top 15 High-Growth Dividend Stocks For October 2025

Oct 1, 2025, 10:58 PM EDT - 2 months ago

Top 15 High-Growth Dividend Stocks For October 2025

ACN DPZ EOG FDX INTU MSCI NDSN


topstockalerts
topstockalerts Dec. 24 at 7:31 PM
Thermo Fisher Scientific has been named Bank of America’s top pick in the Life Sciences Tools space, with the firm raising its price target to $700 and reaffirming a Buy rating. Management projects 3–4% revenue growth in fiscal 2026 and more than 50 basis points of operating margin expansion, excluding benefits from the Clario acquisition, which is expected to add about $0.45 in EPS in its first year. The company is positioned to benefit from favorable industry trends such as reshoring and reduced uncertainty across academic, government, and pharmaceutical markets, while continued innovation and its “trusted partner” strategy should sustain momentum. Recently, Thermo Fisher has seen multiple positive analyst actions, including an upgrade to Overweight from KeyBanc and new Overweight or Buy ratings from Morgan Stanley and Goldman Sachs. The company also announced an expansion of its bioprocessing capabilities across Asia to support the region’s growing biopharmaceutical industry. $TMO
0 · Reply
TechTraderGrok
TechTraderGrok Dec. 24 at 6:00 PM
Bought $TMO at $578.7. From Grok: "Entering long on this dip in a confirmed uptrend with price above rising EMA and SMA, positive MACD, and no immediate catalysts, targeting resistance near 598 over the next few weeks." https://www.techtrader.ai/grokwall/?post=15916&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Kalebrown
Kalebrown Dec. 24 at 4:41 PM
$MCD $LRCX $SHOP $CCZ $TMO 600B just amazing.
0 · Reply
NeuralinkNick
NeuralinkNick Dec. 24 at 3:39 PM
$TMO Forward performance will increasingly reflect discipline in balancing growth ambition with capital efficiency, with outcomes shaped by timing and discipline. Outcomes hinge on delivery, not scale.
0 · Reply
1iquid
1iquid Dec. 20 at 6:43 AM
OptionWizards Tip (education only): Compare the option’s breakeven price to ABT, TMO, or MCD’s recent trading range to assess realistic profit potential. $ABT $TMO $MCD Not financial advice.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:16 PM
Actionable Trade Alert for $TMO: Market Context: $TMO is currently trading at $562.39, showing a bearish sentiment with an RSI of 28.94, indicating it is oversold. The stock is below both the 30-day MA (577.15) and the 50-day MA (566.85), confirming the downward trend. The 60-day high of 602.32 and low of 456.67 suggest a potential for recovery from the lower end of this range. Directional Bias: The oversold RSI presents a potential buying opportunity as the stock may rebound. However, caution is warranted due to the prevailing bearish trend indicated by the moving averages. Trade Plan: - Suggested Entry: $563.00 - Stop Loss: $545.00 (3.2% below entry) - Take Profit Targets: - Target 1: $580.00 (3% gain) - Target 2: $595.00 (5.7% gain) - Target 3: $660.00 (17.3% gain) This plan offers a potential ROI of over 17% on the third target while maintaining a manageable risk. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Dec. 18 at 1:33 PM
Biotech revolution is here, everyone eyes CRISPR stars — but real money in tools. Gold rush: picks and shovels. Biotech "shovels": $ILMN: Sequencing monopoly $TMO: Lab equipment giant $PACB: Long-read leader $DHR: Life science tools $BECT: Diagnostic king
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:03 AM
Actionable Trade Alert for $TMO: Market Context: $TMO is currently trading at $567.51, showing signs of potential recovery after hitting an RSI of 28.18, indicating oversold conditions. The stock is below both its 30-day moving average (MA30) of 577.33 and 50-day moving average (MA50) of 565.8, suggesting bearish sentiment but with a potential reversal opportunity. Directional Bias: The RSI indicates oversold conditions, which may lead to a bullish reversal. The price is also near the 60-day low of 456.67, providing a strong support level. Trade Plan: - Suggested Entry: $570.00 (slightly above current price to confirm upward momentum) - Stop Loss: $550.00 (below recent support) - Take Profit Targets: 1. $580.00 (1.75% ROI) 2. $590.00 (3.95% ROI) 3. $665.00 (17.2% ROI) Monitor price action closely for confirmation of upward movement. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
TalkMarkets
TalkMarkets Dec. 16 at 8:21 PM
Top Down Review Of #Healthcare And #Biotech Stocks: Growth Opportunities In #Biopharma And #Genomics $BMY $TMO $IBB $IHI https://talkmarkets.com/content/etfs/top-down-review-of-healthcare-and-biotech-stocks-growth-opportunities-in-biopharma-and-genomics?post=545089
0 · Reply
ZacksResearch
ZacksResearch Dec. 16 at 1:35 PM
$TMO expands Gibco Bacto CD portfolio — what it means for the stock's momentum 🚀 After announcing new formulations to boost plasmid DNA and protein production, TMO shares rose 0.7% yesterday. This move builds on its legacy in media innovation, potentially propelling its Cell Culture and Cell Therapy business forward. Discover the full impact on TMO here 👉 https://www.zacks.com/stock/news/2804770/tmo-stock-set-to-gain-from-the-expansion-of-gibco-bacto-portfolio?cid=sm-stocktwits-2-2804770-body-24959&ADID=SYND_STOCKTWITS_TWEET_2_2804770_BODY_24959
0 · Reply
ZacksResearch
ZacksResearch Dec. 16 at 11:48 AM
$TMO poised for upside from a quiet growth lever 👀 Thermo Fisher stock is set to gain as it expands its Gibco Bacto portfolio — a clear signal the company is leaning into portfolio growth to drive future performance. See why this expansion matters for TMO 👉 https://www.zacks.com/stock/news/2804770/tmo-stock-set-to-gain-from-the-expansion-of-gibco-bacto-portfolio?cid=sm-stocktwits-2-2804770-teaser-24920&ADID=SYND_STOCKTWITS_TWEET_2_2804770_TEASER_24920
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 6:31 PM
Wells Fargo has adjusted their stance on Thermo Fisher Scientific ( $TMO ), setting the rating to Overweight with a target price of 635 → 675.
0 · Reply
TapeTrack_1721
TapeTrack_1721 Dec. 15 at 4:05 PM
$TMO large cap life sciences, slow grind trend as long as institutions keep accumulating dips
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 5:37 AM
Actionable Trade Alert for $TMO: Market Context: $TMO is currently trading at $572.28, showing a bearish sentiment with an RSI of 39.21, indicating potential oversold conditions. The stock is below its 30-day moving average (MA30) of 576.95 but above the 50-day moving average (MA50) of 564.68, suggesting a possible reversal. Directional Bias: The proximity to the 60-day low of 456.67 and the recent high of 602.32 indicates a volatile range. The ATR of 11.16 supports potential price movement, making this an opportune time for a strategic entry. Trade Plan: - Suggested Entry: $572.28 - Stop Loss: $558.00 (2.5% below entry) - Take Profit Targets: 1. $585.00 (2.2% gain) 2. $600.00 (4.8% gain) 3. $670.00 (17% gain) This plan aims for a significant upside while managing risk effectively. Monitor closely for price action around the MA levels. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
TechTraderGrok
TechTraderGrok Dec. 12 at 9:07 PM
Sold $TMO at $572.13 (-2.3%). From Grok: "Exiting the long position in TMO as price has rejected at 598 resistance with bearish MACD crossover below signal, overbought conditions fading, and pullback toward 550 support signaling potential further downside over the next few weeks, despite intact uptrend." https://www.techtrader.ai/grokwall/?post=15836&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 12 at 1:11 PM
$TMO RSI: 53.92, MACD: 3.0492 Vol: 8.96, MA20: 579.10, MA50: 563.74 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
carcarterq
carcarterq Dec. 12 at 10:26 AM
$LMT $CSCO $INTC $TMO $XOM 2025 US National security strategy It’s critical shift of US strategy for upcoming decades https://ai-stock-valuator-paywall-version-546154778738.us-west1.run.app 2025 US National security strategy US National Security Strategy 2025: 5 Key Takeaways Re-industrialize: Factories return home. Western Hemisphere: Counter China in Latin America. Realism: End nation-building; secure borders. Energy: US oil & gas dominance. Defense: Europe must pay its share. Top Picks: $LMT (Defense), $CSCO (Secure Tech), $INTC (Chips), $XOM (Energy). #AmericaFirst #NationalSecurity #Stocks
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:29 PM
Actionable Trade Alert for $TMO: Market Context: $TMO is currently trading at $576.14, showing a neutral RSI of 52.24, indicating no immediate overbought or oversold conditions. The stock is above its 30-day moving average (MA30) of $576.33, suggesting bullish momentum, while the 50-day moving average (MA50) at $563.68 provides support. Directional Bias: The price is near the 60-day high of $602.32, indicating potential upside. The ATR of 11.99 suggests volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $577.00 - Stop Loss: $563.00 (approximately 2.4% below entry) - Take Profit Targets: 1. $590.00 (2.25% ROI) 2. $600.00 (3.98% ROI) 3. $675.00 (17.15% ROI) This plan allows for a significant upside while maintaining a manageable risk. Monitor closely for market changes. https://privateprofiteers.com
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 11 at 4:09 PM
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 2:13 PM
Citigroup has adjusted their stance on Thermo Fisher Scientific ( $TMO ), setting the rating to Buy with a target price of 580 → 660.
0 · Reply
LiveSquawk
LiveSquawk Dec. 11 at 11:21 AM
$TMO | Citigroup Raises Thermo Fisher Scientific To ‘Buy’ From ‘Neutral’; Raises Price Target To $660 From $580
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 2:33 AM
Actionable Trade Alert for $TMO: Market Context: $TMO is currently trading at $562.95, showing a neutral RSI at 40.11, indicating potential for upward movement as it is not in overbought territory. The price is below both the 30-day MA of $575.19 and the 50-day MA of $560.99, suggesting a bearish short-term trend but possible reversal. Directional Bias: With the 60-day high at $602.32 and the low at $456.67, the current price is closer to the midpoint, indicating a potential bounce back. The ATR of 12.0 suggests moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $565.00 (slightly above the last close) - Stop Loss: $550.00 (to limit downside risk) - Take Profit Targets: 1. $580.00 (3% gain) 2. $590.00 (4.5% gain) 3. $660.00 (17% gain) This plan provides a clear strategy to capitalize on potential upward momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply